ArticleSmart molecules : open access2026
A single-molecule prodrug synergistically suppresses MYC-amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy.
Article in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MYC-amplified osteosarcoma, a poor-prognosis molecular subtype, presents formidable therapeutic challenges due to its aggressive phenotype, chemoresistance, and the "undruggable" oncogenic driver MYC. A single-molecule prodrug, DHU-NO3, was developed to achieve precise synergy between photodynamic therapy (PDT) and nitric oxide (NO) gas therapy for the treatment of MYC-amplified osteosarcoma. This prodrug covalently links the clinically approved photosensitizer methylene blue (MB) to an NO donor and undergoes a sequential activation cascade: reactive oxygen species-triggered MB release, 405 nm light-controlled NO generation, and PDT initiation under 650 nm laser irradiation. In 143B osteosarcoma cells, this temporally coordinated regimen efficiently induces apoptosis and potently suppresses the MYC signaling network. In the 143B osteosarcoma subcutaneous xenograft model, DHU-NO3-mediated sequential phototherapy demonstrated robust tumor growth inhibition with favorable biosafety. This work establishes a spatiotemporally programmable prodrug platform and provides a potent strategy to combat MYC-amplified osteosarcoma by indirect pathway suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.